GSK reports 4.05B voting rights at September 30

Shareholders may use GSK's 4,045,430,485 voting rights as the denominator for determining whether an interest notification is required.

Rhea-AI Filing Summary

GSK plc reported that its issued share capital consisted of 4,316,311,549 Ordinary Shares as of September 30, 2026, including 270,881,064 shares held in Treasury. Total voting rights were 4,045,430,485, which shareholders may use as the denominator for determining whether they must notify the company of an interest or a change in an interest.

Key Figures

Issued Ordinary Shares: 4,316,311,549 shares Shares held in Treasury: 270,881,064 shares Total voting rights: 4,045,430,485 +1 more

4 metrics

Issued Ordinary Shares 4,316,311,549 shares As of September 30, 2026

Shares held in Treasury 270,881,064 shares As of September 30, 2026

Total voting rights 4,045,430,485 As of September 30, 2026; denominator for interest-notification calculations

Nominal value per Ordinary Share 31¼ pence Issued share capital as of September 30, 2026

Key Terms

issued share capital, held in Treasury, denominator, Disclosure Guidance and Transparency Rule 5.6.1R

4 terms

issued share capital financial

"The Company’s issued share capital as at 30 September 2026"

Issued share capital is the total value or number of a company's shares that have been created and given to investors, employees or others; think of it as the slices of a cake that have already been cut and distributed. It matters to investors because it determines ownership percentages, potential voting power and how future share sales can dilute existing holdings, affecting share value and control.

held in Treasury financial

"270,881,064 Ordinary Shares were held in Treasury"

denominator regulatory

"may be used by shareholders as the denominator"

The denominator is the number on the bottom of a fraction that shows the total population or base used to calculate a rate, percentage or ratio — for example, the total shares outstanding when calculating earnings per share, or all trial participants when reporting a safety rate. It matters to investors because changing the denominator (by issuing more shares, changing the population measured, or narrowing the base) can make percentages and per‑unit figures look better or worse even if the underlying raw numbers stay the same, much like changing the size of a pizza makes each slice appear larger or smaller.

Disclosure Guidance and Transparency Rule 5.6.1R regulatory

"in conformity with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rule 5.6.1R"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many voting rights does GSK have?

GSK reported 4,045,430,485 total voting rights as of September 30, 2026. Shareholders may use this figure as the denominator for determining whether they must notify the company of an interest or a change in an interest under the applicable rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 10:57 AM Accepted by SEC EDGAR 10/01/2026 - 10:57 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 1 October 2026, London UK

Total Voting Rights

In conformity with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the ‘Company’) hereby notifies the market of the following:

The Company’s issued share capital as at 30 September 2026 consisted of 4,316,311,549 shares of 31 ¼ pence each (‘Ordinary Shares’), of which 270,881,064 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 4,045,430,485. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

Notifications may be sent to company.secretary@gsk.com.

V A Whyte

Company Secretary

1 October 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: October 01, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc